# Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Study · id `cardio:ct-nct01977482` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01977482](<https://clinicaltrials.gov/study/NCT01977482>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01977482

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

## Technical summary

Registry record NCT01977482. Randomized; triple masking; primary purpose treatment. Start 2013-11-01 (registry gives no type); primary completion 2015-02-01 (actual). Results posted on 2017-02-14.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 216 participants (enrolled count; ClinicalTrials.gov record NCT01977482, source copy `cardio:ctgov-nct01977482-2018-06-08`, retrieved 2026-10-26)
- Start date: 2013-11-01 (registry gives no type) (ClinicalTrials.gov record NCT01977482, source copy `cardio:ctgov-nct01977482-2018-06-08`, retrieved 2026-10-26)
- Primary completion: 2015-02-01 (actual) (ClinicalTrials.gov record NCT01977482, source copy `cardio:ctgov-nct01977482-2018-06-08`, retrieved 2026-10-26)
- Completion: 2015-02-06 (actual) (ClinicalTrials.gov record NCT01977482, source copy `cardio:ctgov-nct01977482-2018-06-08`, retrieved 2026-10-26)
- Results first posted: 2017-02-14 (ClinicalTrials.gov record NCT01977482, source copy `cardio:ctgov-nct01977482-2018-06-08`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Czechia; Denmark; France; Germany; Hungary; Japan; Norway; Poland; Russia; South Korea; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01977482, source copy `cardio:ctgov-nct01977482-2018-06-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01977482-2018-06-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
- Condition: Anaemia
- Intervention (Drug): GSK1278863
- Intervention (Drug): Placebo
- Intervention (Drug): rhEPO
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: 5337a0f4c23700bdde82139adccc06162acfb9921037f710a47ef45dccd1886f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
